Kantonsspital St.Gallen


recently published research projects
Bayer 20324
TRK fusion cancer is rare but presents as a variety of solid tumors. Larotrectinib is a highly selective TRK inhibitor that, in a pooled analysis of patients in phase 1/2 clinical trials, demonstrated an effective and sustained response in the majority of patients with TRK fusion cancer. Because of the limited number of patients treated ...
A multicenter, non-randomized, open-label phase 1b study...
BAY-1895344 und Pembrolizumab bei ausgewählten Tumoren mit genetischen Alterationen von ATM.
A Study to Evaluate Imetelstat (GRN163L) in...
A Study to Evaluate Imetelstat (GRN163L) in Transfu-sion-Dependent Subjects with IPSS Low or Intermedi-ate-1 Risk Myelodysplastic Syndrome (MDS) that is Re-lapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
other recently published research projects
number of projects
number of ongoing projects